ClinicalTrials.gg
Not yet recruitingNCT07743489Updated Aug 17, 2026

RB-PDT for Fusarium Keratitis: The LUMIERE Study

A Phase 3 interventional study of Rose Bengal Photodynamic Therapy and Sham RB-PDT in Fusarium Keratitis, sponsored by Stanford University. Not yet recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Stanford University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
434
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Keratitis with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Keratitis · United States.

Planned enrollment
4th of 25
434 · median 60
Started
2027
the only one that year
Phase 3
3 of 34
1 open now
Registered
34th of 34
by date
Lead sponsor
2 of 34
Stanford University

Among the 34 studies in Keratitis with a site in United States, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2027, is one of 3 in phase 3, and was the 34th registered.

Keratitis

108 studies on the registry are indexed under Keratitis; 19 are open to participants now.

Browse Keratitis studies →

Open to participants now

4 of the 34 studies in Keratitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Keratitis studies recruiting now, 6 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Keratitis with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter trial with recruitment planned at ophthalmology clinics specializing in corneal diseases in India, Brazil, and at Stanford University and Bascom Palmer Eye Institute in the United States. Fusarium keratitis is common in tropical and subtropical regions like Florida, India and Brazil, which will facilitate access to the required number of participants. The study aims to recruit a total of 434 participants (217 per group).

Read the detailed description

Participants with fusarium corneal ulcers will be randomized in a 1:1 fashion to one of two arms:

  • Group 1, RB-PDT: natamycin 5%/Amphotericin B 0.15% plus RB-PDT
  • Group 2, Sham RB-PDT: natamycin 5%/Amphotericin B 0.15% plus sham RB-PDT

Participants will begin topical antimicrobial upon initial diagnosis: applied to the affected eye every hour while awake for the first week, then every 2 hours while awake for 3 weeks. Thereafter, application will be tapered at the discretion of the treating physician based on response to therapy.

RB-PDT/sham RB-PDT will occur within 5 days of initial smear/culture. For Group 1, Rose Bengal (0.1% RB in 0.9% sodium chloride) will be applied in 3-minute intervals to the de-epithelialized cornea for 30 minutes followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Participants in Group 2 will undergo a sham procedure using topical balanced salt solution and pen light covered with a green filter. Study participants will undergo repeat scraping and culture of the corneal ulcer 30 minutes after the assigned RB-PDT procedure.

A second RB-PDT/sham RB-PDT procedure and repeat smear/culture will occur one week after the first procedure, following the same protocol.

03

Conditions studied

  • Fusarium Keratitis

Browse trials for

Keywords

  • fusarium keratitis
  • rose bengal
  • RB-PDT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of culture positive fusarium fungal keratitis
  • Age over 18 years
  • Moderate to severe vision loss, defined as Snellen visual acuity of 20/40 (6/12) to 20/400 (6/120)
  • Corneal thickness ≥350 µm, as measured on AS-OCT
  • Basic understanding of the study as determined by the physician
  • Commitment to return for follow up visits

Exclusion criteria

Exclusion Criteria:

  • History of to Rose Bengal
  • Evidence of concomitant infection on exam, gram stain, or confocal microscopy (i.e. herpes, both bacteria and acanthamoeba on gram stain)
  • History of intraocular surgery within the last three months*
  • Impending or frank perforation at recruitment
  • Involvement of sclera at presentation
  • Presence of desmestocele at recruitment
  • Non-infectious or keratitis
  • History of corneal transplantation
  • Pinhole visual acuity worse than 20/200 in the unaffected eye
  • Participants who are decisionally and/or cognitively impaired
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
434 participants (estimated)

Study arms

  • Active comparator
    Group 1: RB-PDT

    Group 1 participants will receive natamycin 5%/Amphotericin B 0.15% plus RB-PDT

    Drug: Rose Bengal Photodynamic Therapy

  • Sham comparator
    Group 2: Sham RB-PDT

    Group 2 participants will receive natamycin 5%/Amphotericin B 0.15% plus sham RB-PDT

    Drug: Sham RB-PDT

Interventions

  • DrugRose Bengal Photodynamic Therapy

    RB-PDT/sham RB-PDT will occur within 5 days of initial smear/culture. For Group 1, Rose Bengal (0.1% RB in 0.9% sodium chloride) will be applied in 3-minute intervals to the de-epithelialized cornea for 30 minutes followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). A second RB-PDT procedure and repeat smear/culture will occur one week after the first procedure, following the same protocol.

  • DrugSham RB-PDT

    Participants in Group 2 will undergo a sham procedure using topical balanced salt solution and pen light covered with a green filter. Study participants will undergo repeat scraping and culture of the corneal ulcer 30 minutes after the assigned RB-PDT procedure. A second sham RB-PDT procedure and repeat smear/culture will occur one week after the first procedure, following the same protocol.

06

What researchers measure

Primary outcomes

  1. BSCVA at 3 months

    Best spectacle-corrected visual acuity measured in logMAR at 3 month follow-up visit

    Time frame: 3 months post-op

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Apr 2029, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 4, 2026
StartEst.
Jan 2027
Primary completionEst.
Apr 2029
CompletionEst.
Jan 2030
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07743489
Collaborators
University of Miami, Aravind Eye Care System, Federal University of São Paulo
Responsible party
Jennifer Rose-Nussbaumer (Professor, Stanford University) — Principal investigator
First posted
Aug 4, 2026
Start date
Jan 2027 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Aug 17, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion